Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019

被引：12
作者：
Lythgoe, Mark P. [1 ]
Krell, Jonathan [1 ]
Mahmoud, Sarah [2 ]
Mills, Emily C. [3 ]
Vasudevan, Aishwarya [3 ]
Savage, Philip [3 ]
机构：
[1] Imperial Coll London, Hammersmith Hosp, Dept Surg & Canc, Cane Rd, London W12 0HS, England
[2] Imperial Coll Healthcare NHS Trust, Canc Serv, London W6 8RF, England
[3] Brighton & Sussex Univ Hosp NHS Trust, Dept Oncol, Brighton BN2 5BE, E Sussex, England
来源：
DRUG DISCOVERY TODAY | 2021年 / 26卷 / 02期
关键词：
D O I：
10.1016/j.drudis.2020.11.011
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Analysis of new anticancer drugs licensed in the UK found that 44 new therapies were approved from 2015 to 2019. No other 5-year period has produced as many new therapies. Most new drugs are kinase inhibitors (KIs, N = 18) and monoclonal antibodies (mAbs, N = 16) with only one classical cytotoxic chemotherapy (CC) licensed. The average median treatment duration has risen by 55 days to 318 days (263 days in 2010?2014). Drug costs have escalated; an average treatment course now costs ?62 343, compared to ?35 383 in 2010?2014. New drugs are delivering significant clinical benefits with longer treatment durations. However, the financial burden is greater, heralding economic challenges for healthcare providers.
引用
收藏
页码：301 / 307
页数：7
相关论文
共 20 条
[1]   The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014-2018 [J].
Bhimani, Jenna ;
Philipps, Lara ;
Simpson, Lawrence ;
Lythgoe, Mark ;
Soultati, Aspasia ;
Webb, Andrew ;
Savage, Philip .
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (01) :93-98
[2]   Cancer Treatment in the Genomic Era [J].
Doherty, Gary J. ;
Petruzzelli, Michele ;
Beddowes, Emma ;
Ahmad, Saif S. ;
Caldas, Carlos ;
Gilbertson, Richard J. .
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 88, 2019, 88 :247-280
[3]   Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center [J].
Hall, Evan ;
Zhang, Jenny ;
Kim, Eun Jeong ;
Hwang, Grace ;
Chu, Gilbert ;
Bhatia, Shailender ;
Reddy, Sunil .
CANCER MEDICINE, 2020, 9 (06) :2106-2112
[4]   The cost of cancer in Europe 2018 [J].
Hofmarcher, Thomas ;
Lindgren, Peter ;
Wilking, Nils ;
Jonsson, Bengt .
EUROPEAN JOURNAL OF CANCER, 2020, 129 :41-49
[5]   Pricing in the Market for Anticancer Drugs [J].
Howard, David H. ;
Bach, Peter B. ;
Berndt, Ernst R. ;
Conti, Rena M. .
JOURNAL OF ECONOMIC PERSPECTIVES, 2015, 29 (01) :139-162
[6]   Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer: Current Status, Recent Advances, and Future Directions [J].
Kamatham, Saivaishnavi ;
Shahjehan, Faisal ;
Kasi, Pashtoon M. .
CURRENT COLORECTAL CANCER REPORTS, 2019, 15 (04) :112-121
[7]   Towards individualized therapy for metastatic renal cell carcinoma [J].
Kotecha, Ritesh R. ;
Motzer, Robert J. ;
Voss, Martin H. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (10) :621-633
[8]   A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation [J].
Lala, Mallika ;
Li, Tommy Ruosi ;
de Alwis, Dinesh P. ;
Sinha, Vikram ;
Mayawala, Kapil ;
Yamamoto, Noboru ;
Siu, Lillian L. ;
Chartash, Elliot ;
Aboshady, Hesham ;
Jain, Lokesh .
EUROPEAN JOURNAL OF CANCER, 2020, 131 :68-75
[9]   Targeted agents and immunotherapies: optimizing outcomes in melanoma [J].
Luke, Jason J. ;
Flaherty, Keith T. ;
Ribas, Antoni ;
Long, Georgina V. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (08) :463-482
[10]   Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: Interim results from the phase 2 KEYNOTE-100 study [J].
Matulonis, Ursula A. ;
Shapira-Frommer, Ronnie ;
Santin, Alessandro ;
Lisyanskaya, Alla Sergeevua ;
Pignata, Sandro ;
Vergote, Ignace ;
Raspagliesi, Francesco ;
Sonke, Gabe S. ;
Birrer, Michael ;
Provencher, Diane M. ;
Sehouli, Jalid ;
Colombo, Nicoletta ;
Gonzalez-Martin, Antonio ;
Oaknin, Ana ;
Ottevanger, P. B. ;
Rudaitis, Vilius ;
Katchar, Kia ;
Wang, Zhen ;
Ruman, Jane ;
Ledermann, Jonathan A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12